Ab Initio talks about product development strategy at ARCS 2022

Dr Will Glover, Ab Initio’s Chief Operating Officer presented on the Podium at ARCS2022. Will’s presentation highlighted the importance of having a robust and focused R&D to product strategy and how Ab Initio can take a new therapeutic through to IND and manufacture.

The session entitled, Product development strategy: From bright idea to commercial success was sponsored by Biointelect

The session sponsored by Biointelect discussed the various pathways to commercialisation. A panel discussion about the key success strategies and required skills to ensure a sustainable business model with viable commercial outcomes and also pitfalls to avoid followed. In addition, the panel highlighted key differences in the commercialisation pathways for medical devices and pharmaceutical products in terms of their research and development strategy, regulatory strategies, reimbursements, clinical trials, intellectual property and risk management.